Ahmedabad based Pharmaceutical Company Eris Lifesciences Acquires Zomelis Trademark from Novartis

As a result of innumerable efforts in the development of medical technology and medical innovations by India, it became world’s most accessible and trustworthy destination for medical expertise including health care facilities and best quality medicines and drugs. Owing to this advancement, a number of companies dealing in generic medicines as well as medicines for chronic and acute therapeutic segments established in India. One such company is Eris Lifesciences Private Limited.

Eris Lifesciences was incorporated on 25th January 2007 by the Founder and Managing Director, Mr Amit Bakshi. It is headquartered at Prahladnagar, Ahmedabad in Gujarat and deals with development, manufacturing and marketing of products linked with lifestyle-related issues that are generally chronic and acute in nature. Its products are manufactured with the highest level of safety and are designed to cure and minimize disorders tied with cardiovascular diseases, diabetes, gastroenterology and gynaecological diseases. Eris Lifesciences is recognized as one of the Top 30 companies in the Indian Branded Formulations Market.

On December 3rd 2019, this renowned medicine manufacturer made headlines after its statement of acquisition of the trademark rights over the anti-diabetes medicine named Zomelis, originally manufactured by the Swiss pharmaceutical multi-national giant, Novartis AG for consideration of a whopping amount of $13 million. This drug Zomelis is an anti-diabetic drug for vildagliptin based formulations and is specifically used in the treatment of Type-2 diabetes. On acquisition of the said trademark rights, Mr Amit Bakshi commented, “Zomelis is a strong brand amongst the super-speciality prescriptions and has been promoted for close to 10 years. Our inorganic growth strategy continues as we explore good opportunities to strengthen our product offering for patients.”

As a matter of fact, Eris Lifesciences has acquired a number of pharmaceutical trademarks in the past including UTH, Kinedex and Amay Pharma with an intention to make their place in nutraceuticals and IVF industry. In addition, it acquired the business portfolio of Strides Pharma Science Limited, previously known as Strides Shashun Limited, in the year 2017 for approximately ₹500 crores. Eris Lifesciences is recognized as one of the top 10 pharmaceutical manufactures of anti-diabetic drugs in the Indian Market. The company began marketing of recently acquired Zomelis drug from 10th December 2019.

To read more articles log on to - https://www.trademarkclick.com/education-blog/